Sign In
Buy JNJ
$241.00
+1.92 (+0.80%)
At Close: Jun 24, 2026
Buy 3 June Fortune 500 Industry Dividend Leaders (Watch 4 More)
08:27am, Friday, 28'th Jun 2024
The June/July 2024 edition of Fortune Magazine revealed the 500 biggest U.S. companies by-revenue and profits. Dogcatcher's quest for dividend buys focused-on 66 industry-eaders (IL) using YCharts 6/2
Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks With Over 3% Dividend Yields
07:30am, Friday, 28'th Jun 2024
During times of turbulence and uncertainty in the markets, even when markets are at all-time highs, many investors turn to dividend-yielding stocks. These are often companies that have high free cash
Investors Heavily Search Johnson & Johnson (JNJ): Here is What You Need to Know
10:06am, Thursday, 27'th Jun 2024
Recently, Zacks.com users have been paying close attention to Johnson & Johnson (JNJ). This makes it worthwhile to examine what the stock has in store.
2 Incredible Dividend Growth Stocks to Buy Right Now
09:00am, Thursday, 27'th Jun 2024
Dividend growth stocks have a remarkable history of generating above-average returns for investors. Here's a breakdown of two of the best stocks in the category.
Is Johnson & Johnson Stock a Buy?
04:23am, Thursday, 27'th Jun 2024
Johnson & Johnson is trying a new approach to resolve thousands of outstanding talc lawsuits. The company's operations are growing in the mid-single digits, and investors can expect more of the same i
Sell Alert: 3 Dividend Aristocrats That May Kill Your Passive Income Snowball
10:08pm, Wednesday, 26'th Jun 2024
Dividend stocks are my favored way for generating passive income for retirement. Passive income is generated with minimal effort once set up, and can snowball beautifully as dividends are reinvested.
The 3 Smartest Dow Stocks to Buy With $1000 Right Now
12:53pm, Wednesday, 26'th Jun 2024
While investors often overlook the Dow Jones Industrial Average in favor of the S&P 500 and the Nasdaq 100, the Dow comprises some of the highest-quality businesses in the world. The top Dow stocks to
Johnson & Johnson (JNJ) Stock Declines While Market Improves: Some Information for Investors
06:50pm, Tuesday, 25'th Jun 2024
Johnson & Johnson (JNJ) closed the most recent trading day at $147.19, moving -1.29% from the previous trading session.
Is Johnson & Johnson the Best Dividend Stock for You?
06:54am, Tuesday, 25'th Jun 2024
You can confidently buy and hold Johnson & Johnson indefinitely. Its steady, high-single-digit returns can stack up over time.
Two High Conviction Dividend Buys For This Upside-Down Market
08:05am, Saturday, 22'nd Jun 2024
FOMO is driving stock market decisions, especially with meme stocks like GameStop and high-flying AI stocks. That's why I prefer discounted dividend stocks over growth stocks, and highlight two picks
3 High-Yield Dividend Stocks Near Their 52-Week Lows to Buy and Hold
06:03am, Saturday, 22'nd Jun 2024
Pfizer has a lot of new drugs on the market, but its stock has been beaten down. Johnson & Johnson stock is down even though both its medical technology and pharmaceutical businesses reported signific
2 Top Stocks to Buy Now for Years of Passive Income
04:45am, Saturday, 22'nd Jun 2024
These dividend stocks have different business models, but each has something to lend to a long-term investor's portfolio. Johnson & Johnson is focusing on the next era of growth, and its strategy is w
J&J (JNJ) Seeks Expanded Use of Tremfya for Crohn's Disease
09:50am, Friday, 21'st Jun 2024
J&J (JNJ) seeks label expansion for Tremfya for treating moderately to severely active Crohn's disease. This marks the second sBLA filing for Tremfya in three months.
Johnson & Johnson Completes Acquisition of Proteologix, Inc.
07:30am, Friday, 21'st Jun 2024
NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) announced today that it has successfully completed the acquisition of Proteologix, Inc., a privately-held biotechnology company focu
Submission is supported by 48-week results from the Phase 3 GALAXI and GRAVITI programs TREMFYA® is the only IL-23 inhibitor to demonstrate strong endoscopic outcomes with subcutaneous (SC) induction
